Market Research Reports

Pharmacovigilance Market (Phases of Drug Development: Preclinical Studies, Clinical Trial Phase I, II, III & IV or Post Marketing Surveillance; Type of Methods: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, & EHR Mining; Type of Service: In-House & Contract Outsourcing) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

151pages
Published Date: 2015-03-30

Description


Intensifying regulatory expectations, tougher inspection system, and instant need for patient reporting boost the adoption rate of pharmacovigilance among pharmaceutical companies. Rise in the prevalence of acute and chronic diseases has consequently led to an increase in the incidences of drug consumption, thus leading to growth in the number of adverse drug events and drug toxicity cases. Furthermore, safety regulations, risk of high-profile safety issues, large volume of post-market events to be reviewed along with negative media coverage have bound the pharmaceutical players to take support of various outsourcing services for drug monitoring. Two major outsourcing providers preferred by pharmaceutical manufacturers for pharmacovigilance services are namely, traditional CROs (e.g. Covance, Inc., Quintiles Transnational, INC Research, etc.) and BPOs (e.g. Capgemini, Cognizant, Infosys Ltd., Tata Consultancy Services Limited, etc.). Outsourcing services do not only help in cost saving, but also support process efficiency. Pharmaceutical companies are now entering into long-term partnerships/service agreements with CROs and BPOs to reduce the pharmacovigilance process related expenditure, incurred right from drug discovery to post-marketing approvals. In addition, pharmacovigilance requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting due to which pharmaceutical companies are opting for outsourced pharmacovigilance services in order to reduce the burden of clerical functions as well as capital expenditures. 

This report provides a detailed analysis of the global pharmacovigilance market and assists in understanding various market regulating factors. The market overview section in this report provides analysis of the overall market trends and market dynamics such as market driving factors, restraining factors, and opportunities, which currently administrate the dynamics of the overall pharmacovigilance market. Additionally, the segment also provides and predicts the future circumstances of the market. Market monitoring tools such as Porter’s five forces analysis is also included in this study to provide analysis about the competition in the pharmacovigilance market and market attractiveness in various regions across the world. Competitive analysis tools such as market share analysis and market attractive analysis have also been included in the market overview section of the report to deliver a comprehensive status of the players in the global pharmacovigilance market. The executive summary provided in this report reflects the highlights of the study scope and the overall market in a summarized form. Furthermore, it includes a market snapshot, which provides a glance at the current scenario of the global pharmacovigilance market in terms of current and future market size and growth. 

The global pharmacovigilance market is segmented on the basis of clinical trial phases, type of methods, service providers, and geography. Based on clinical trial phases, the pharmacovigilance market is segmented into preclinical studies, phase I trial, phase II trial, phase III trial, and phase IV trial (post marketing surveillance). Based on the methods, this study segments the market into spontaneous reporting, targeted reporting, cohort event monitoring, Intensified ADR, and Reporting EHR mining. Based on service providers, the global pharmacovigilance market is categorized into in-house and contract outsourcing. The market size estimations for the period from 2012 to 2020 have been provided for each segment in terms of USD million. Compounded annual growth rates (CAGR %) for each segment has been provided for the period between 2014 and 2020, considering 2013 as the base year. 

In terms of regional analysis, the global pharmacovigilance market has been segmented into four key geographies: North America, Europe, Asia Pacific, and Rest of World (RoW). Market revenue estimations for each of these geographies have been provided in the report for the period from 2012 to 2020 in terms of USD million, considering 2013 as the base year for calculations and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period from 2014 to 2020 has also been provided along with market size estimations. This study also provides recommendations for players of the global pharmacovigilance market, which include aspects that may play a decisive role in improving the market share.

The report concludes with in-depth profiles of leading players, which include key information about the major organizations dynamically involved in the global pharmacovigilance market. The report profiles the key market players in terms of company overview, financial overview, product portfolio, business strategies, and recent developments. The key companies profiled in this study are Accenture, Plc, Clinquest Group B.V., Cognizant Technology Solutions, Covance, Inc. ICON, Plc, iMED Global Corporation, inVentiv Health, Inc., Parexel International Corporation, Pharmaceutical Product Development LLC, PRA Health Sciences, Inc., Quintiles Transnational Holdings Inc, F. Hoffmann-La Roche Ltd., Sanofi , Synowledge LLC, Wipro Limited. Market share analysis of the organizations operating in the pharmacovigilance market would help new entrants to understand key business policies and identify product portfolio of established companies.
The global pharmacovigilance market is segmented as follows:

Pharmacovigilance Market, by Phases of Drug Development
  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV or Post Marketing Surveillance 
Pharmacovigilance Market, by Type of Methods 
  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining
Pharmacovigilance Market, by Type of Service
  • In-House
  • Contract Outsourcing
Pharmacovigilance Market, by Geography
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Table of Contents



Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Global Pharmacovigilance Market Dynamics
3.1 Introduction
3.2 Market Drivers
      3.2.1 Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug Event Monitoring
      3.2.2 Rise in the Cases of Adverse Drug Reactions and Drug Toxicity Would Boost Demand for Pharmacovigilance Activities
      3.2.3 Rise in Adoption of Outsourcing Services Expected to Accentuate the Market Growth
3.3 Market Restraints
      3.3.1 High Risk Associated with Data Security in Pharmacovigilance Outsourcing
      3.3.2 Lack of Availability of Skilled Labor might Hinder the Market Growth
      3.3.3 Inadequate Pharmacovigilance System for Herbal Products in Asia Pacific Might Hamper the Market Growth
3.4 Market Opportunities
      3.4.1 Huge Scope for Rapid Growth of Pharmacovigilance Market in Emerging Economies
      3.4.2 Shift in Preference for Outsourcing among Various Pharmaceutical and Life Sciences Companies
3.5 Porter’s Five Forces Analysis: Global Pharmacovigilance Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography
3.7 Competitive Landscape
      3.7.1 Market Share Analysis: Global Pharmacovigilance Market, 2013 (Value %)

Chapter 4 Global Pharmacovigilance Market, by Phases of Drug Development
4.1 Overview
      4.1.1 Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2012 – 2020 (USD Million)
      4.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Clinical Trial Phases, 2013 & 2020 (Value %)
4.2 Preclinical Studies
      4.2.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.3 Phase I
      4.3.1 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.4 Phase II
      4.4.1 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.5 Phase III
      4.5.1 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.6 Phase IV or Post Marketing Surveillance
      4.6.1 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)

Chapter 5 Global Pharmacovigilance Market, By Type of Methods
5.1 Overview
      5.1.1 Global Pharmacovigilance Market Revenue, by Type of Methods , 2012 – 2020 (USD Million)      
      5.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
5.3 Spontaneous Reporting
      5.3.1 Global Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
5.4 Intensified ADR Reporting
      5.4.1 Global Intensified ADR Reporting Market Revenue, 2012 – 2020 (USD Million)
5.5 Targeted Spontaneous Reporting
      5.5.1 Global Targeted Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
5.6 Cohort Event Monitoring
      5.6.1 Global Cohort Event Monitoring Market Revenue, 2012 – 2020 (USD Million)
5.7 EHR Mining
      5.7.1 Global EHR Mining Market Revenue, 2012 – 2020 (USD Million)

Chapter 6 Global Pharmacovigilance Market, by Type Service Providers
6.1 Overview
      6.1.1 Global Pharmacovigilance Market Revenue, by Type of Service Providers , 2012 – 2020 (USD Million)
      6.1.2 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
6.2 In-house Pharmacovigilance
      6.2.1 Global In-House Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
6.3 Contract Outsourcing
      6.3.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)

Chapter 7 Global Pharmacovigilance Market, by Geography
7.1 Overview
      7.1.1 Global Pharmacovigilance Market Revenue, by Geography, 2012 – 2020 (USD Million)
7.2 North America
      7.2.1 North America Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.3 Europe
      7.3.1 Europe Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.4 Asia Pacific
      7.4.1 Asia Pacific Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.5 Rest of the World (RoW)
      7.5.1 RoW Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)

Chapter 8 Recommendations

Chapter 9 Company Profiles
9.1 Accenture plc
      9.1.1 Company Overview
      9.1.2 Financial Overview
      9.1.3 Product Portfolio
      9.1.4 Business Strategies
      9.1.5 Recent Developments
9.2 Bristol-Myers Squibb
      9.2.1 Company Profile
      9.2.2 Financial Overview
      9.2.3 Product Portfolio
      9.2.4 Business Strategies
9.3 Clinquest Group B.V.
      9.3.1 Company Overview
      9.3.2 Financial Overview
      9.3.3 Product Portfolio
      9.3.4 Business Strategies
      9.3.5 Recent Developments
9.4 Cognizant Technology Solutions
      9.4.1 Company Overview
      9.4.2 Financial Overview
      9.4.3 Product Portfolio
      9.4.4 Business Strategies
      9.4.5 Recent Developments
9.5 Covance, Inc.
      9.5.1 Company Overview
      9.5.2 Financial Overview
      9.5.3 Product Portfolio
      9.5.4 Business Strategies
      9.5.5 Recent Developments
9.6 F. Hoffmann-La Roche Ltd.
      9.6.1 Company Overview
      9.6.2 Financial Overview
      9.6.3 Product Portfolio
      9.6.4 Business Strategies
      9.6.5 Recent Development
9.7 GlaxoSmithKline plc (GSK)
      9.7.1 Company Overview
      9.7.2 Financial Overview
      9.7.3 Product Portfolio
      9.7.4 Business Strategies
      9.7.5 Recent Developments
9.8 ICON plc
      9.8.1 Company Overview
      9.8.2 Financial Overview
      9.8.3 Product Portfolio
      9.8.4 Business Strategy
      9.8.5 Recent Developments
9.9 iGATE Corporation
      9.9.1 Company Overview
      9.9.2 FINANCIAL Overview
      9.9.3 Product Portfolio
      9.9.4 Business Strategies
      9.9.5 Recent Developments
9.10 iMEDGlobal Corporation
      9.10.1 Company Overview
      9.10.2 Financial Overview
      9.10.3 Product Portfolio
      9.10.4 Business Strategies
      9.10.5 Recent Developments
9.11 inVentiv Health, Inc.
      9.11.1 Company Overview
      9.11.2 Financial Overview
      9.11.3 Product Portfolio
      9.11.4 Business Strategies
      9.11.5 Recent Developments
9.12 Novartis International AG
      9.12.1 Company Overview
      9.12.2 Financial Overview
      9.12.3 Product Portfolio
      9.12.4 Business Strategies
      9.12.5 Recent Developments
9.13 PAREXEL International Corporation
      9.13.1 Company Overview
      9.13.2 Financial Overview
      9.13.3 Product Portfolio
      9.13.4 Recent Developments
9.14 Pfizer, Inc.
      9.14.1 Company Overview
      9.14.2 Financial Overview
      9.14.3 Product Portfolio      
      9.14.4 Business Strategies
      9.14.5 Recent Developments
9.15 Pharmaceutical Product Development, LLC. (PPD)
      9.15.1 Company Overview
      9.15.2 Financial Overview
      9.15.3 Product Portfolio
      9.15.4 Business Strategies
      9.15.5 Recent Developments
9.16 PRA Health Sciences, Inc.
      9.16.1 Company Overview
      9.16.2 Financial Overview
      9.16.3 Product Portfolio
      9.16.4 Business Strategies
      9.16.5 Recent Developments
9.17 Quintiles Transnational Holdings, Inc.
      9.17.1 Company Overview
      9.17.2 Financial Overview
      9.17.3 Product Portfolio
      9.17.4 Business Strategies
      9.17.5 Recent Developments
9.18 Sanofi
      9.18.1 Company Overview
      9.18.2 Financial Overview
      9.18.3 Product Portfolio
      9.18.4 Business Strategies
      9.18.5 Recent Developments
9.19 Synowledge LLC
      9.19.1 Company Overview
      9.19.2 Financial Overview
      9.19.3 Product Portfolio
      9.19.4 Business Strategies
      9.19.5 Recent Developments
9.20 Wipro Limited
      9.20.1 Company Overview
      9.20.2 Financial Overview
      9.20.3 Product Portfolio
      9.20.4 Business Strategies


List of Figures

FIG. 1 Drug Safety From Molecule to Market
FIG. 2 Pharmacovigilance: Market Segmentation
FIG. 3 Global Pharmacovigilance Market, by Phases of Drug Development, 2013 (USD Million)
FIG. 4 Global Pharmacovigilance Market, by Type of Service Providers, 2013 (USD Million)
FIG. 5 Global Pharmacovigilance Market, by Type of Methods, 2013 (USD Million)
FIG. 6 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2103 (Value %)
FIG. 7 Porter’s Five Forces Analysis: Global Pharmacovigilance Market
FIG. 8 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography (2013)
FIG. 9 Global Pharmacovigilance Market Share Analysis, by Key Players, 2013 (%)
FIG. 10 Safety Services : Product Lifecycle
FIG. 11 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2013 & 2020 (Value %)
FIG. 12 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Comparison of Methods: Pharmacovigilance reporting
FIG. 18 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
FIG. 19 Global Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 Global Intensified ADR Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 Global Targeted Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Global Cohort Event Monitoring Market Revenue, 2012 – 2020 (USD Million)
FIG. 23 Global EHR Mining Market Revenue, 2012 – 2020 (USD Million)
FIG. 24 End-to-End Safety Across the Lifecycle
FIG. 25 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
FIG. 26 Global In-House Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 27 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 28 North America Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 29 Europe Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 30 Asia Pacific Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 31 RoW Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 32 Accenture plc.: Annual Revenue 2011– 2013 (USD Billion)
FIG. 33 Bristol-Myers Squibb: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 34 Cognizant Technology Solutions: Annual Revenue, 2011– 2013 (USD Million)
FIG. 35 COVANCE, Inc.: Annual Revenue, 2011– 2013 (USD Million)
FIG. 36 F. Hoffmann-La Roche Ltd., Annual Revenue: 2011 – 2013 (USD Million)
FIG. 37 GlaxoSmithKline plc (GSK): Annual Revenue, 2011 – 2013 (USD Million)
FIG. 38 ICON plc: Annual Revenue, 2011 – 2013 ( USD Million)
FIG. 39 iGATE Corporation: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 40 Novartis International AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 41 PAREXEL International Corporation: Annual Revenue 2011 – 2013 (USD Million)
FIG. 42 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 43 PRA Health Sciences, Inc., Annual Revenue: 2012 – 2014 (USD Million)
FIG. 44 Quintiles Transnational Holdings, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 45 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 46 Wipro Limited: Annual Revenue 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Market Snapshot : Pharmacovigilance Market
TABLE 2 Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2012 – 2020 (USD Million)
TABLE 3 Global Pharmacovigilance Market Revenue, by Type of Methods, 2012 – 2020 (USD Million)
TABLE 4 Global Pharmacovigilance Market Revenue, by Type of Service Providers, 2012 – 2020 (USD Million)
TABLE 5 Global Pharmacovigilance Market Revenue, by Geography, 2012 – 2020 (USD Million)

Other Reports


Free Market Analysis


Pharmacovigilance is a key component of an effective drug regulation system for monitoring and evaluating adverse drug reactions (ADRs). Pharmacovigilance activities are an important part of clinical research and are growing at a significant pace. At present, the global network of pharmacovigilance centers, harmonized by Uppsala Monitoring Centre, are operating on the global level for appropriate functioning of the process of drug safety monitoring across the world. Large volume of international ADR reports collected in a central database would serve as a contributing factor to the effort of national drug regulatory authorities, thus improving the safety profile of drugs that would help avoid drug related disasters. In addition, growing public health awareness and expectation in relation to the safe use of medicines and medical interventions are some of the major factors contributing to the growth of the global pharmacovigilance market. Furthermore, increasing number of national pharmacovigilance centers globally is playing a definitive role in augmenting public awareness about drug safety, thereby supporting the growth of the pharmacovigilance market in the next few years. However, the pharmacovigilance market is facing several hurdles and challenges to develop a better health care system. Challenges that are acting as major restraining factors for pharmacovigilance market are web-based drug information and sales, perceptions to harm and benefit, high risk associated with data security and unavailability of skilled professionals.

Based on phases of drug development, the global pharmacovigilance market has been segmented into preclinical studies, clinical trial phase I, II, III and IV or post marketing surveillance. The phase IV or post marketing surveillance segment accounted for the largest share of the pharmacovigilance market in terms of revenue in 2013. Rise in the number of safety concerns pertaining to the marketed product, increasing need for developing systems for comparing safety profiles of similar pharmaceutical products and growth in public health awareness campaigns regarding drug safety issues among the people are the major factors attributed to the high growth of the segment. In addition, the clinical trial phase III segment is expected to grow at the highest CAGR due to the rising need for drug safety monitoring and evaluation in phase III before the drug manufacturer can apply for market authorization application. Additionally, phase III clinical trial focuses on drug safety and efficacy in diverse sub-groups, wherein the risk-benefit ratio is developed, monitored and updated accordingly. Biopharmaceutical companies are in the process of developing advanced clinical trial phases that would be more specific to drug safety. Rigorous pharmacovigilance activities are expected to be made compulsory during the commencement of various clinical trial phases that would be helpful in actively managing high-risk medicines.

Based on methods of performing pharmacovigilance, the market has been categorized into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining. Spontaneous reporting method was the largest segment in terms of revenue in 2013. Factors attributed to the growth of the segment are easy simulation of realistic datasets that provides better drug evaluation and comparison, and better assessment of automatic signal generation methods proposed within pharmacovigilance. The segment is also expected to maintain its lead during the forecast period from 2014 to 2020, as in this method, healthcare professionals are encouraged to report adverse reactions after which preventive measures such as adding warnings to the product labeling or recalling the product are taken. Moreover, spontaneous reporting is the most appropriate method of detecting new ADRs and generates safety signals that require further examination. 

Based on types of services, the pharmacovigilance market has been segmented into in-house and contract outsourcing. The contract outsourcing service segment accounted for the largest share in 2013. The segment is estimated to grow at the highest CAGR during the forecast period. The major factor driving the growth of the segment is the increasing need of pharmaceutical companies to shift focus from non-core to core business activities by outsourcing their pharmacovigilance services. Moreover, outsourcing of pharmacovigilance services is aimed at minimizing operational cost and financial loss incurred from product approval delays or recalls, thereby propelling the growth of the contract outsourcing service segment.

Geographically, North America accounted for the largest share of the global pharmacovigilance market in 2013. Factors attributed to the growth of the pharmacovigilance market in North America are increasing mortality rate due to ADRs and escalating patient concerns regarding the safety and efficacy of pharmaceutical products. According to the Centers for Disease Control and Prevention (CDC), ADRs account for more than 100,000 deaths annually and are among the top 10 leading causes of death in the U.S. Moreover, cost benefit obtained by shifting high costs of in-house pharmacovigilance activities to CROs is boosting the growth of the market in North America. However, Asia Pacific is anticipated to witness the highest growth during the forecast period. Factors attributed to the high growth are increased demand for stringent health care regulations in Asia, presence of large patient pool and increasing volume of clinical trials being conducted in this region. According to an article published in the National Center for Biotechnology Information in 2014, serious ADRs are witnessed in 6.7% of patients in India. Additionally, demand for effective pharmacovigilance services and drug safety in increasing in the region due to large number of clinical trials and clinical research activities being carried out in various countries in Asia.

The global pharmacovigilance market is fragmented due to the presence of numerous established as well as emerging organizations. The top companies operating in the pharmacovigilance market are Cognizant Technology Solutions, Accenture plc, Bristol-Myers Squibb, Covance, Inc., Clinquest Group B.V., ICON plc, F. Hoffmann-La Roche Ltd., inVentiv Health, Inc., GlaxoSmithKline plc, iGATE Corporation, Novartis International AG, Wipro Limited, Quintiles Transnational Holdings, Inc., Synowledge LLC, Pharmaceutical Product Development, LLC, (PPD), Sanofi, PAREXEL International Corporation, Pfizer, Inc., and iMEDGlobal Corporation. 

pharmacovigilance-market


To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Report tailored as you need

If you feel this report needs customization, feel free to contact us. Our team of expert analyst can fulfil your requirements.

CUSTOMIZE REPORT

Upcoming Report

Payment
Copyright @ Transparency Market Research